<DOC>
	<DOCNO>NCT01239394</DOCNO>
	<brief_summary>Ofatumumab drug work attach CD20 molecule find surface cancerous B cell , trigger death cell . It approve FDA treatment another B-cell cancer , chronic lymphocytic leukemia , also evidence success people 's B-cell lymphoma relapse initial treatment . In research study look see ofatumumab effective safe treat previously untreated B-cell NHL .</brief_summary>
	<brief_title>Ofatumumab Initial Systemic Treatment Indolent B-cell Lymphoma</brief_title>
	<detailed_description>- Participants receive ofatumumab week 8 week intravenous infusion ( Days 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 ) . - Participants see weekly 8 week treatment period follow test procedure perform : Blood test , performance status physical examination .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm indolent CD20+Bcell NHL follow histology : follicular lymphoma , grade 12 ; Marginal zone lymphoma ( extranodal , nodal splenic ) ; small lymphocytic lymphoma ; lowgrade Bcell lymphoma otherwise specify CD20+ expression Measurable disease , define least one lesion accurately measure least one dimension 20mm great CT scan MRI No previous chemotherapy , antibody therapy radioimmunotherapy disease . Patients previously treat external beam radiation alone eligible 18 year age old Life expectancy great 3 month ECOG Performance status 0 , 1 2 Organ function describe protocol Women childbearing potential men must agree use adequate contraception prior study entry duration study participation Prior chemotherapy , antibody therapy radioimmunotherapy lymphoma Participants may receive investigational agent Participants know brain metastasis History allergic reaction attribute compound similar chemical biologic composition ofatumumab Prior exposure ofatumumab target antiCD20 therapy include rituximab Known HIV positivity Positive serology Hepatitis B Positive serology Hepatitis C Participants candidate curative radiotherapy , unless radiation therapy consider toxic ( abdominal disease ) , refuse patient New York Heart Association Classification III IV heart disease Uncontrolled intercurrent illness include , limited ongoing active infection optimally treat antibiotic , unstable angina pectoris , psychiatric illness/social situation would limit compliance study requirement Pregnant breastfeed woman History different malignancy ineligible except follow circumstance : Individuals history malignancy eligible diseasefree least one year deem investigator low risk recurrence malignancy . Individuals follow cancer eligible even diagnose treat within past 1 year : localized prostate cancer , prostate cancer elevate PSA measurable disease CT scan bone scan , cervical cancer situ , breast ductal carcinoma situ nonmelanoma skin cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>NHL</keyword>
	<keyword>ofatumumab</keyword>
</DOC>